Show simple item record

dc.creatorVladimirov, Sote
dc.creatorAgbaba, Danica
dc.date.accessioned2019-09-02T10:55:26Z
dc.date.available2019-09-02T10:55:26Z
dc.date.issued2002
dc.identifier.issn0004-1963
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/377
dc.description.abstractMany novel types of asthma therapeutic procedures have been investigated in the past decade. A vast amount of work in the 5-LO inhibitor and LT1-receptor antagonist area has resulted in a various of compounds being identified for clinical trails, and several compounds are used in the clinic. The impact of the LT1-receptor antagonist and 5-LO inhibitors on alergy therapy will be significant, if these compounds have an antiinflammatory effect within their mechanism. The area with possibly the most promise is selective inhibitors of phosphodiesterase enzymes (PDEs). Selective inhibitors of three isoenzymes of PDEs (PDE III, IV and V) may be possess both activity; bronchodilatory and anti-inflammatory effects. This results imply that this agents may lead to a re-examination and further subclassification of various types of asthma diseases.en
dc.publisherSavez farmaceutskih udruženja Srbije, Beograd
dc.rightsopenAccess
dc.sourceArhiv za farmaciju
dc.titleEikozanoidi u terapiji astmesr
dc.typearticle
dc.rights.licenseBY-SA
dcterms.abstractAгбаба, Даница; Владимиров, Соте; Еикозаноиди у терапији астме; Еикозаноиди у терапији астме;
dc.citation.volume52
dc.citation.issue1-2
dc.citation.spage41
dc.citation.epage54
dc.citation.other52(1-2): 41-54
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs//bitstream/id/1940/375.pdf
dc.identifier.rcubconv_4
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record